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Abstract: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) 
represents the most common genetic subtype of adult ALL (20%–30%) and accounts for 
approximately 50% of all cases in the elderly. It has been considered the subgroup of ALL 
with the worst outcome. The introduction of tyrosine kinase inhibitors (TKIs) allows complete 
hematologic remission virtually in all patients, with improved disease-free survival and overall 
survival. Nevertheless, the emergence of resistant mutations in BCR-ABL1 may require different 
TKI strategies to overcome the patient’s resistance and disease relapse. Here, we report a Ph+ 
B-ALL case with persistent minimal residual disease (MRD) after treatment with dasatinib. 
The patient expressed the P190BCR-ABL1 isoform and a novel BCR-ABL1 mutation, p.Y440C. 
The latter is in the C-terminal lobe of the kinase domain, which likely induces deviations 
in the protein structure and activity and destabilizes its inactive conformation. The treatment 
was substituted by bosutinib, which binds to the active conformation of the protein, prior to 
allogeneic bone marrow transplant to overcome the lack of a complete response to dasatinib. 
These findings strengthen the importance of BCR-ABL1 mutational screening in Ph+ patients, 
particularly for those who do not achieve complete molecular remission.
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Introduction
Acute lymphoblastic leukemia (ALL) is a clonal disease in which immature lymphoid 
cells accumulate mainly in the bone marrow and peripheral blood. The disease is very 
heterogenous, comprising several hematological, cytogenetic and molecular groups. 
The Philadelphia chromosome (Ph) is the most frequent genetic abnormality in adult 
ALL (Ph+ ALL), representing 20%–30% of the B-lineage cases (B-ALL) but only 
5% of the pediatric cases. Ph+ ALL frequency increases with age, accounting for 
approximately 50% of all cases in the elderly.1,2
The translocation that characterizes the Ph chromosome, t(9;22)(q34;q11), involves 
the fusion of the following two genes: BCR and ABL1. In Ph+ ALL, the most frequently 
expressed isoform of BCR-ABL1, accounting for 70% of the cases, is the P190, in 
which exon 1 of BCR is fused to exon 2 of ABL1 (e1a2).3,4 The remaining Ph+ ALL 
cases are associated with P210BCR-ABL1. The transforming potential of the P190 isoform is 
believed to result from the partial loss of BCR domains, namely, the guanine exchange 
factor/dbl-like domain that mediates the communication with several Ras proteins, 
which are crucial for the regulation of signaling pathways and processes, such as cell 
proliferation, differentiation, adhesion, apoptosis and migration.4–7 More recently, 
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Reckel et al8 demonstrated the existence of strong differ-
ences in the interactome and tyrosine phosphoproteome 
between P190 and P210 signaling pathways. P190 interacts 
predominantly with the AP2 adaptor complex involved in the 
regulation of clathrin-mediated endocytosis, whereas P210 
interacts mostly with the phosphatase Sts1, showing a stron-
ger activation of the Stat5 transcription factor and the Erk1/2 
kinases, while P190 activates the Lyn kinase.8 Nonetheless, 
both transcripts translate for a constitutively active tyrosine 
kinase that deregulates cell proliferation, differentiation and 
survival, thus constituting a critical molecular target.
In chronic myeloid leukemia (CML), in which all patients 
test positive for BCR-ABL1, tyrosine kinase inhibitor (TKI) 
therapy revolutionized prognosis. The same applies for Ph+ 
ALL, in which complete remission can be achieved in 95% 
of the patients.4 Molecular monitoring of Ph+ hematological 
diseases has become an integral part of the clinical manage-
ment of these patients, from diagnosis to follow-up surveil-
lance. This is valid not only for transcript identification 
and quantification (critical for monitoring minimal disease) 
but also for mutational analysis of the ABL1 domain of the 
chimeric transcript. Indeed, BCR-ABL1 variations are one 
of the mechanisms that lead to TKI resistance, may be due 
to pre-existent mutations (primary resistance accounts for 
one-third of the patients) or mutations that arise from TKI 
treatment pressure (acquired resistance).9 For Ph+ ALL 
patients who fail to respond to imatinib (IM, first-generation 
TKI), a second- or third-generation TKI (dasatinib, nilotinib, 
bosutinib and ponatinib) should be administered according 
to the results of the mutational analysis.10 Several studies 
report the impact of ABL1 mutational screening in Ph+ ALL 
patients,11–13 in whom more than 100 mutations have been 
reported in the ABL1 kinase domain, frequently positioned in 
the: 1) phosphate-binding loop (P-loop); 2) ATP/IM binding 
site; 3) catalytic domain (SH2 contact and C-loop); and 4) 
the activation loop (A-loop) (Figure 1).11 IM-resistant Ph+ 
ALL patients frequently harbor the T315I mutation (ATP/IM 
binding site) and will only respond to ponatinib.14,15
Herein, we describe a Ph+ B-ALL patient expressing 
the P190BCR-ABL1 isoform and a novel BCR-ABL1 mutation 
in the region that encodes for the C-terminal lobe domain 
of the protein.
Case presentation
A 31-year-old male was diagnosed with B-ALL (92% blasts), 
characterized as Ph+ by cytogenetics (70% fluorescence in 
situ hybridization [FISH]-positive; Figure 2A; “Methods” 
section in Supplementary materials). The patient was treated 
with a pediatric-inspired regimen (Dana Farber Cancer 
Institute 01-175)16 with the addition of dasatinib 140 mg/day. 
On day 29 of therapy induction, the patient was in complete 
remission. However, minimal residual disease (MRD) was 
detected via reverse transcription nested-PCR according to 
the standardized procedure established by van Dongen et al17 
Figure 1 Map of the most recurrent amino acid substitutions in the BCr-aBL1 kinase domain in ph+ clinical samples.
Notes: Highlighted mutations are the most frequent, usually associated with IM resistance. Numbering of residues is according to normal aBL1 protein. Key structural motifs 
within the kinase domain are indicated as follows: p-loop, phosphate binding loop; IM binding, aTp/IM binding region; C-loop, kinase catalytic domain; a-loop, activation loop; 
C-lobe, C-terminal lobe.
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Figure 2 Cytogenetic (A) and molecular (B) analyses of ph+ aLL patient’s bone marrow sample.
Notes: (A) Interphase FIsH image depicting a ph+ nucleus, 46,XY,t(9;22)(q34.1;q11.2), using LsI BCr/aBL1 Dual Color, Dual Fusion translocation probe. The image was 
provided by the Hematology Department of Hospital dos Capuchos. (B) ABL1 and BCR-ABL1 molecular analyses: (B1) control PCR amplification of ABL1 (expected amplicon 
size=296 bp) and (B2) nested-PCR amplification of e1a2 (P190BCr-aBL1) isoform (expected amplicon size=381 bp). pCr products (1 µL) were resolved via 2% agarose gel 
electrophoresis. Ladder, Generuler DNa Ladder Mix sM0331.






















(“Methods” section in Supplementary materials and 
Table S1), which shows a sensitivity level of 10−4 for 
BCR-ABL1 transcripts (Figure 2B). Molecular analysis of 
the patient’s white blood cells revealed the expression of 
P190BCR-ABL1 (“Methods” section in Supplementary materi-
als and Figure S1), the most common isoform in Ph+ ALL. 
MRD was confirmed in a second evaluation 4 weeks later. 
As per the protocol, this finding triggered a proposal for 
an allogeneic transplant from a human leukocyte antigen 
(HLA)-matched sibling.
Bone marrow samples were further analyzed for mutations 
associated with TKI resistance so as to reduce BCR-ABL1 
expression before the allogeneic bone marrow transplant. 
Mutational analysis via Sanger sequencing (“Methods” sec-
tion in Supplementary materials) showed a point mutation in 
the ABL1 domain of the fusion transcript, c.1319A.G, which 
lies in the region that translates for the C-terminal lobe of the 
kinase domain, p.Tyr440Cys (Figure 3). Despite this varia-
tion being present in 20% of the BCR-ABL1-expressing cells 
at follow-up (day 29; Figure 3A2), it had not been identified 
at diagnosis (day 1; Figure 3A1). These results indicate that 
this might be acquired resistance probably due to selective 
pressure on mutant clones upon dasatinib treatment. In fact, 
the in-frame mutation in leukemic cells is not present in ABL1 
from non-leukemic cells, indicating a somatically acquired 
rather than a germline mutation. This was confirmed by the 
analysis of the genomic DNA of the patient’s epithelial cells 
(Figure 3A3).
Following extensive bioinformatics and literature 
analyses (discussed in the “Discussion” section), and as an 
effort to achieve molecular remission, the TKI regimen was 
changed to bosutinib in post-induction therapy. After 7 weeks 
on bosutinib, BCR-ABL1 levels did decrease when compared 
to those on dasatinib (Figure 3B). Nevertheless, MRD was 
still present, and thus the patient proceeded to transplant. He 
died 7 months posttransplant from complications of acute 
graft vs host disease.
Discussion
TKI regimens have greatly improved the therapeutic out-
come of patients with Ph+ ALL. However, each individual’s 
sensitivity to each TKI must be considered for a successful 
therapeutic outcome. Similar to what is recommended for 
CML, Ph+ ALL patients who do not respond to one of the 
available TKIs should undergo mutational screening for an 
assessment of markers of drug resistance mechanisms.4,12
The herein newly described BCR-ABL1 nucleotide 
substitution, c.1319A.G (codon TAC.TGC), results in 
the amino acid alteration, p.Tyr440Cys (Figure 3). The sub-
stitution of a highly conserved amino acid across different 
species (Table S2), coupled to a shift between a large amino 
acid (tyrosine) and a small amino acid with a thiol side chain 
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Figure 3 ph+ aLL patient’s novel BCr-aBL1 point mutation and disease molecular monitoring.
Notes: (A) p190BCr-aBL1 protein structure indicating the position of the detected mutation. sequencing chromatograms displaying: (A1) BCR-ABL1 nucleotide sequence from 
ph+ aLL patient’s white blood cells at the time of diagnosis; (A2) BCR-ABL1 nucleotide sequence from ph+ aLL patient’s white blood cells at day 29 after diagnosis and 
treatment initiation. Chromatogram peak analysis indicates that the variation is present in 20% of the total ph+ clones; (A3) ABL1 nucleotide sequence from ph+ aLL patient’s 
epithelial cells; and (A4) ABL1 from control individual (WT). p-loop: phosphate binding loop; IM binding: aTp/IM binding region; C-loop: kinase catalytic domain; a-loop: 
activation loop; and C-lobe: C-terminal lobe. (B) BCR-ABL1 mRNA relative quantification in bone marrow samples at the time of diagnosis and follow-up. qPCR data were 
normalized to ABL1 and compared to transcript levels at the time of diagnosis. patient started induction chemotherapy and dasatinib after diagnosis. Treatment was switched 
to bosutinib 5 months after diagnosis and maintained for 7 weeks (until the 7-month time point).
Abbreviations: aLL, acute lymphoblastic leukemia; IM, imatinib; ph+, philadelphia chromosome positive; WT, wild-type.
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(cysteine), is likely to induce deviations in correct folding of 
the protein. To understand the possible effect of this mutation 
in BCR-ABL1 structure, we probed the sequence through 
MutationTaster, which predicts changes in the transcript splice 
sites, as well as alterations to protein features.18 Using Support 
Vector Machine and sequence information, a decrease in the 
stability of protein structure due to the p.Tyr440Cys mutation 
is predicted with a confidence score of −0.898.19 DISOclust 
software analysis also shows an increase in the disorder prob-
ability score in the mutated ABL1 domain, particularly in 
residues located after the Y440C mutation (Figure S2).20
Point mutations within the C-terminal lobe region of 
BCR-ABL1 have been described to impair protein structure. 
For example, the well-studied E459K substitution makes 
the protein inactive conformation unstable even though the 
amino acid position is not near the ATP/IM binding site. 
Since IM only binds to the inactive conformation of BCR-
ABL1, patients harboring this mutation typically do not 
respond to this TKI or other first-line TKIs, but are more 
sensitive to bosutinib that can bind to the active conformation 
of the protein.21 On this basis, the treatment was altered to 
bosutinib, which induced a reduction in MRD after 7 weeks 
(Figure 3B), to set up for allogeneic transplant.
To the best of our knowledge, this is the first report 
regarding the c.1319A.G variation in the ABL1 domain of 
BCR-ABL1 of a refractory Ph+ patient to dasatinib treatment. 
The predicted change in protein features is likely to induce 
resistance to TKIs and should be carefully addressed upon 
during treatment choice.
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FISH analysis was performed in interphase cells using the 
LSI BCR/ABL1 Dual Color, Dual Fusion translocation probe 
(Abbott Molecular, Des Plaines, IL, USA), according to 
the manufacturer’s instructions. A total of 100 nuclei were 
scored at diagnosis. This analysis was carried out using a 
fluorescence microscope (Eclipse Ci; Nikon, Tokyo, Japan), 
and image capture was performed using Isis FISH Imaging 
System V 5.7.1 (MetaSystems, Altlussheim, Germany).
rNa extraction and cDNa synthesis
RNA was extracted from bone marrow white blood cells. 
Briefly, 5 mL of sample was mixed with 10 mL of red blood 
cell lysis solution (5 mM MgCL
2
, 10 mM NaCl and 10 mM 
Tris-HCl; pH 7) and centrifuged at 400× g for 5 minutes. 
The procedure was repeated to lyse residual red blood cells. 
White blood cell pellet was subjected to total RNA extraction 
using SV Total RNA Isolation System (Promega Corpora-
tion, Fitchburg, WI, USA), according to the manufacturer’s 
instructions. RNA was resuspended in nuclease-free water 
and stored at −80°C until use. RNA concentration and purity 
were determined by UV spectrophotometry. Total RNA 
extracted (100 ng) was reverse transcribed into cDNA, 
using the NZY M-MuLV First-Strand cDNA Synthesis kit 
(Nzytech, Lisbon, Portugal).
BCr-aBL1 molecular analysis
Nested-PCR amplification of BCR-ABL1 was performed 
using primers specified in Table S1. The PCR mixture compo-
nents included 1× NH
4
 reaction buffer (Bioline, Taunton, MA, 
USA), 2.5 mM MgCl
2
, 0.15× Hi-Specific additive (Bioline), 
200 µM dNTPs, 400 nM primers and 0.02 U/µL BIOTAQ 
DNA polymerase (Bioline). Outer PCR was performed using 
3 µL of cDNA in a 50 µL reaction, under the following con-
ditions: initial denaturation at 95°C for 5 minutes; 30 cycles 
of 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 
1.5 minutes; and a final extension step at 72°C for 10 minutes. 
Inner PCR was performed using 1 µL of outer PCR product 
in a 50 µL reaction, under the following conditions: initial 
denaturation at 95°C for 5 minutes; 30 cycles of 94°C for 
15 seconds, 55°C for 30 seconds, 72°C for 1 minute; and a 
final extension step at 72°C for 10 minutes. A control PCR, 
for the amplification of ABL1, was also performed using prim-
ers depicted in Table S1. All PCR products were visualized 
via 2% agarose gel electrophoresis and subsequently analyzed 
by Sanger sequencing at STABVIDA (Setúbal, Portugal).























Figure S1 alignment of ph+ aLL patient e1a2 nucleotide sequence (seq 1) with BCR-ABL1 e1a2 reference sequence from GenBank aF113911.1 (seq 2).
Note: arrow indicates the breakpoint in this BCR-ABL1 isoform.
Abbreviations: aLL, acute lymphoblastic leukemia; ph+, philadelphia chromosome positive.
Table S2 aBL1 protein alignment between different species demonstrates the conservation of the affected amino acid
Species AA position Alignment
Homo sapiens mutated (ph+ aLL patient) 440 LWeIaTYGMspCpGIDLsQVYeL
H. sapiens wild-type 440 LWeIaTYGMspYpGIDLsQVYeL
Pan troglodytes 459 LWeIaTYGMspYpGIDLs
Macaca mulatta 168 LWeIaTYGMspYpGIDLsQVYeL
Felis catus 459 LWeIaTYGMspYpGIDLs
Mus musculus 459 LWeIaTYGMspYpGIDLs
Gallus gallus 440 LWeIaTYGMspYpGIDLsQVYeL
Takifugu rubripes 801 LWeIaTYGMspYpGIDL
Danio rerio 459 LWeIaTYGMspYpGIDLsQ
Drosophila melanogaster 587 LWeIaTYGMspYpaIDLTDVYHK 
Caenorhabditis elegans 509 LWeIaTYGMapYpGVeLsNVYGL
Abbreviations: aLL, acute lymphoblastic leukemia; ph+, philadelphia chromosome positive.
Relative quantification of BCR-ABL1 transcripts 
via qpCr
Quantitative monitoring of BCR-ABL1 e1a2 transcript 
was performed in bone marrow samples using a Corbett 
Rotor-Gene 6000 thermal cycler (Qiagen NV, Venlo, the 
Netherlands) and NZY qPCR Green Master Mix (Nzytech). 
The reaction mixture was prepared in a final volume of 
10 µL with 1 µL of cDNA and 100 nM of each primer: 
outer PCR primers for BCR-ABL1 transcript identifica-
tion or ABL1 control primers, specified in Table S1. qPCR 
conditions included an initial denaturation at 95°C for 
15 minutes and 40 cycles of 95°C for 20 seconds and 60°C 
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Figure S2 DIsOclust disorder prediction results.
Note: Disorder probability score by residue number in BCr-aBL1 harboring the Y440C on the aBL1 domain.

























for 50 seconds. qPCR data were analyzed by the Ct method 
(2−ΔΔCt), in which relative gene expression is given by quan-
tification of the gene of interest (BCR-ABL1) normalized to 
internal control gene (ABL1), relative to control condition 
(diagnostics sample).
Genomic DNa extraction from patient’s epithelial cells
Buccal epithelial cells were collected from the subject of this 
study by twirling a swab on the inner cheeks for 1 minute. 
The swab was separated from the stick and inserted into a 
microtube containing 440 µL of lysis buffer (50 mM Tris; 
1% SDS). The tube was vortexed for several minutes to 
promote the release of most epithelial cells. The swab was 
removed, and 20 µL of proteinase K (100 mg/mL dissolved 
in TE buffer: 10 mM Tris-HCl; 0.1 mM EDTA pH 8) was 
mixed with the cell suspension and incubated for 10 minutes 
at 50°C. After adding 40 µL of 5 M NaCl, 500 µL of isopro-
panol was gently mixed with the DNA-containing solution 
and allowed to stand for 5 minutes at room temperature. 
The sample was centrifuged for 5 minutes at 12,000× g; the 
supernatant was removed; and the dry pellet was resuspended 
in 100 µL of TE buffer. DNA concentration and purity were 
determined by UV spectrophotometry. DNA was stored at 
4°C until use.
Mutational analysis of aBL1 exon 8 on genomic DNa
PCR amplification of ABL1 exon 8 of patient’s epithelial 
cells was performed using the following primers: forward 
5 ′-CTCAAATAATCCTCCCACTTCA and reverse 
5 ′-CCTGGAATGCCCACATATAC. PCR mixture 
components included 1× NH
4
 reaction buffer (Bioline), 
2.5 mM MgCl
2
, 0.15× Hi-Spec additive (Bioline), 200 µM 
dNTPs, 400 nM primers, 0.02 U/µL BIOTAQ DNA poly-
merase (Bioline) and 20 ng of gDNA. PCR conditions 
included an initial denaturation at 95°C for 5 minutes; 
30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, 
72°C for 1 minute; and a final extension step at 72°C for 
10 minutes.
sequence alignments
Basic Local Alignment Search Tool (BLAST), from the 
National Center for Biotechnology Information (NCBI), 
was used to align all obtained sequences, via Sanger 
sequencing, with the following reference sequences: BCR-
ABL1 e1a2 (GenBank AF113911.1) and ABL1 (GenBank 
NM005157.5).
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